TREMFYA® is a prescription medicine used to treat adults with moderately to severely active ulcerative colitis.

Administration and Dosage:

Ulcerative Colitis:

  • Induction:

    • 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8.
  • Maintenance:

    • 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter.
    • Or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter.
    • Use the lowest effective recommended dosage to maintain therapeutic response.

Indication:

TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with:

  • Moderately to severely active ulcerative colitis (1.3)

Common Side Effects:

The most common side effects of TREMFYA include:

  • Respiratory Tract Infections
  • Headache
  • Injection Site Reactions
  • Joint Pain (Arthralgia)
  • Diarrhea
  • Stomach Flu (Gastroenteritis)
  • Fungal Skin Infections
  • Herpes Simplex Infections
  • Bronchitis

These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

More information:

Please read the full Prescribing Information and Patient Information for TEPEZZA® and discuss any questions you have with your doctor.

HAVE QUESTIONS?

We are happy to help!
Name